Peregrine Capital Management LLC bought a new stake in shares of Agios Pharmaceuticals Inc (NASDAQ:AGIO) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 179,970 shares of the biopharmaceutical company’s stock, valued at approximately $9,625,000. Peregrine Capital Management LLC owned approximately 0.26% of Agios Pharmaceuticals at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the business. BlackRock Inc. raised its stake in Agios Pharmaceuticals by 16.3% during the 1st quarter. BlackRock Inc. now owns 4,529,580 shares of the biopharmaceutical company’s stock valued at $160,709,000 after acquiring an additional 636,186 shares in the last quarter. State Street Corp raised its stake in Agios Pharmaceuticals by 1.3% during the 1st quarter. State Street Corp now owns 1,909,309 shares of the biopharmaceutical company’s stock valued at $67,742,000 after acquiring an additional 24,523 shares in the last quarter. First Trust Advisors LP raised its stake in Agios Pharmaceuticals by 26.9% during the 2nd quarter. First Trust Advisors LP now owns 1,590,391 shares of the biopharmaceutical company’s stock valued at $85,054,000 after acquiring an additional 337,397 shares in the last quarter. Casdin Capital LLC raised its stake in Agios Pharmaceuticals by 29.7% during the 1st quarter. Casdin Capital LLC now owns 1,070,000 shares of the biopharmaceutical company’s stock valued at $37,964,000 after acquiring an additional 245,000 shares in the last quarter. Finally, Rock Springs Capital Management LP raised its stake in Agios Pharmaceuticals by 64.5% during the 1st quarter. Rock Springs Capital Management LP now owns 1,055,500 shares of the biopharmaceutical company’s stock valued at $37,449,000 after acquiring an additional 414,000 shares in the last quarter. 97.73% of the stock is currently owned by hedge funds and other institutional investors.

In other news, insider Christopher Bowden sold 3,583 shares of Agios Pharmaceuticals stock in a transaction on Wednesday, May 20th. The stock was sold at an average price of $50.01, for a total transaction of $179,185.83. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders own 3.16% of the company’s stock.

Shares of AGIO stock traded down $2.13 on Friday, reaching $45.32. 646,496 shares of the company’s stock traded hands, compared to its average volume of 497,019. Agios Pharmaceuticals Inc has a 12-month low of $27.77 and a 12-month high of $56.74. The company has a debt-to-equity ratio of 0.17, a quick ratio of 8.27 and a current ratio of 8.41. The business’s 50 day moving average price is $51.61 and its two-hundred day moving average price is $47.27.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.36) by $0.05. Agios Pharmaceuticals had a negative return on equity of 59.38% and a negative net margin of 182.49%. The business had revenue of $37.30 million for the quarter, compared to the consensus estimate of $37.17 million. During the same quarter in the previous year, the company posted ($1.87) earnings per share. Agios Pharmaceuticals’s revenue for the quarter was up 42.4% compared to the same quarter last year. On average, sell-side analysts predict that Agios Pharmaceuticals Inc will post -4.67 earnings per share for the current fiscal year.

Several equities analysts have recently issued reports on AGIO shares. Guggenheim lifted their price target on Agios Pharmaceuticals from $60.00 to $66.00 and gave the company a “buy” rating in a research report on Monday, June 15th. Citigroup lifted their price target on Agios Pharmaceuticals from $64.00 to $75.00 and gave the company a “buy” rating in a research report on Monday, June 15th. Needham & Company LLC started coverage on Agios Pharmaceuticals in a research report on Thursday. They set a “buy” rating and a $71.00 price target on the stock. BidaskClub cut Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, Canaccord Genuity reiterated a “buy” rating and set a $72.00 price target on shares of Agios Pharmaceuticals in a research report on Friday. One analyst has rated the stock with a sell rating, four have given a hold rating and twelve have given a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $68.77.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.

Featured Story: Stock Market – What is a circuit breaker?

Institutional Ownership by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.